The Macroaxis Fundamental Analysis lookup allows users to check a given indicator for any equity or select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please check also Equity Screeners to view more equity screening tools
Price to Sales AnalysisPrice to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
About Price to SalesThe most important factor to remember is that the price of equity takes a firm's debt into account, whereas the sales does not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
|Compare to competition|
Based on latest financial disclosure the price to sales indicator of BioShares Biotechnology Products is roughly 5.6 times. This is 47.37% higher than that of the Bio Shares family, and 47.56% higher than that of Health category, The Price to Sales for all etfs is 677.78% lower than the firm.
BioShares Biotechnology Fundamental Drivers Relationships
BioShares Biotechnology Products is third largest ETF in price to earning as compared to similar ETFs. It is second largest ETF in price to sales as compared to similar ETFs fabricating about 0.31 of Price to Sales per Price to Earning. The ratio of Price to Earning to Price to Sales for BioShares Biotechnology Products is roughly 3.22